HUT74245A - Pharmaceutical compositions for attenuating lung capillary leak - Google Patents

Pharmaceutical compositions for attenuating lung capillary leak Download PDF

Info

Publication number
HUT74245A
HUT74245A HU9501980A HU9501980A HUT74245A HU T74245 A HUT74245 A HU T74245A HU 9501980 A HU9501980 A HU 9501980A HU 9501980 A HU9501980 A HU 9501980A HU T74245 A HUT74245 A HU T74245A
Authority
HU
Hungary
Prior art keywords
methotrexate
dose
administered
mice
administration
Prior art date
Application number
HU9501980A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9501980D0 (en
Inventor
Suresh S Kerwar
Michael M Wick
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of HU9501980D0 publication Critical patent/HU9501980D0/hu
Publication of HUT74245A publication Critical patent/HUT74245A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU9501980A 1994-07-01 1995-06-30 Pharmaceutical compositions for attenuating lung capillary leak HUT74245A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/269,702 US5593671A (en) 1994-07-01 1994-07-01 Method of attenuating lung capillary leak in a mammal

Publications (2)

Publication Number Publication Date
HU9501980D0 HU9501980D0 (en) 1995-08-28
HUT74245A true HUT74245A (en) 1996-11-28

Family

ID=23028336

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9501980A HUT74245A (en) 1994-07-01 1995-06-30 Pharmaceutical compositions for attenuating lung capillary leak

Country Status (9)

Country Link
US (1) US5593671A (enExample)
EP (1) EP0692251A1 (enExample)
JP (1) JPH0826998A (enExample)
KR (1) KR960003728A (enExample)
AU (1) AU2335195A (enExample)
CA (1) CA2152981A1 (enExample)
HU (1) HUT74245A (enExample)
NZ (1) NZ272476A (enExample)
TW (1) TW294596B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1115397B1 (en) 1998-08-28 2006-05-24 Intarcia Therapeutics, Inc. Compositions for mitigating the adverse effects of interleukin-2
US6544504B1 (en) 1999-07-28 2003-04-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
AU2001283191A1 (en) * 2000-08-10 2002-02-25 Uab Research Foundation Compositions containing an inhibitor of dihydrofolate reductase and a folate
AU2005227263A1 (en) * 2004-03-05 2005-10-06 Novartis Vaccines And Diagnostics, Inc. In vitro test system for predicting patient tolerability of therapeutic agents
DE102006033837A1 (de) 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK86988A (da) * 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf

Also Published As

Publication number Publication date
JPH0826998A (ja) 1996-01-30
KR960003728A (ko) 1996-02-23
TW294596B (enExample) 1997-01-01
NZ272476A (en) 1997-06-24
HU9501980D0 (en) 1995-08-28
EP0692251A1 (en) 1996-01-17
AU2335195A (en) 1996-01-18
CA2152981A1 (en) 1996-01-02
US5593671A (en) 1997-01-14

Similar Documents

Publication Publication Date Title
US5372808A (en) Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5932208A (en) Compositions and methods for the use of such compositions in human therapeutics, characterized by the association of a muramyl peptide with a cytokine
EP0493468B1 (en) Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists
CA1339070C (en) Treatment of diseases associated with cysteine deficiency
CA2341742A1 (en) Activation and protection of t-cells (cd4+ and cd8+) using an h2 receptor agonist and other t-cell activating agents
Schiller et al. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer
EP1201236B1 (en) Use of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for preventing or treating viral myocarditis
US20040120926A1 (en) Reactive oxygen metabolite inhibitors for use in compositions and methods of treatment
Atkinson et al. GM‐CSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and lymphocytes
EP0553294B1 (en) The manufacture of compositions for the treatment of cell proliferation disorders
HUT74245A (en) Pharmaceutical compositions for attenuating lung capillary leak
EP0663826B1 (en) Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies
Nakamura et al. Combination effect of recombinant human interleukin 1α with antitumor drugs on syngeneic tumors in mice
Marumo et al. Immunologic study of human recombinant interleukin-2 (low dose) in patients with advanced renal cell carcinoma
US5108993A (en) Pharmaceutical composition comprising zidovudine and inosiplex or components thereof for the treatment of aids-related syndromes
Rizzo et al. Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma
US5026544A (en) Methods and compositions for inhibiting the growth of neoplastic cells
AU672288B2 (en) Rejection inhibitor for transplants and IL-1 production inhibitor
Takahashi et al. Recombinant human granulocyte colony‐stimulating factor (G‐CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard‐risk myeloid leukemia
West et al. Biological response modifiers and chemotherapeutic agents that alter interleukin 2 activities
KR102273445B1 (ko) 셀레질린을 유효성분으로 포함하는 급성 골수성 백혈병의 예방 또는 치료용 약학 조성물
RU2311196C1 (ru) Средство "лизолакт", потенцирующее противоопухолевую активность цитотоксических препаратов
JPH05271095A (ja) 抗癌剤
US20040116354A1 (en) Supplementary immunotherapeutics to be used after lung cancer removal
Rhoads Biological Response Modifiers and Chemotherapeutic Agents

Legal Events

Date Code Title Description
DFC4 Cancellation of temporary prot. due to refusal